DOI QR코드

DOI QR Code

A 10-year-old Boy with Microscopic Hematuria and Renal Biopsy Findings Mimicking Fabry Disease

  • Chung, Woo Yeong (Department of Pediatrics, Busan Paik Hospital, Inje University) ;
  • Kang, Mi Seon (Department of Pathology, Busan Paik Hospital, Inje University)
  • Received : 2016.08.17
  • Accepted : 2016.10.10
  • Published : 2016.10.30

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme ${\alpha}-galactosidase$ A, resulting in the accumulation of glycosphingolipids within the lysosomes of various cell types. It has a wide spectrum of clinical phenotypes, and renal failure is a serious complication. Fabry disease is confirmed either by measurement of ${\alpha}-galactosidase$ A activity or by genetic testing for GLA mutations. Renal biopsy findings on light microscopy, specifically enlarged podocytes with foamy cytoplasm, and osmiophilic inclusion bodies in the cytoplasm in all types of renal cells on electron microscopy, are characteristic of this disease. The predominant differential diagnosis is iatrogenic phospholipidosis in association with certain drugs that can cause cellular injuries indistinguishable from Fabry disease. Here, we report the case of a 10-year-old boy with microscopic hematuria who underwent a renal biopsy that showed morphological findings consistent with Fabry disease, although the patient had neither a GLA mutation nor a history of drug consumption. Six years later, spontaneous regression of this renal pathology was observed in a second renal biopsy examination.

Keywords

References

  1. Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30. https://doi.org/10.1186/1750-1172-5-30
  2. Muller-Hocker J, Schmid H, Weiss M, Dendorfer U, Braun GS. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. Hum Pathol 2003;34:285-89. https://doi.org/10.1053/hupa.2003.36
  3. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. .An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-99. https://doi.org/10.1056/NEJM199102073240607
  4. Ko YH, Kim HJ, Roh YS, Park CK, Kwon CK, Park MH. Atypical Fabry's disease.An oligosymptomatic variant. Arch Pathol Lab Med 1996;120:86-9.
  5. Germain DP.General aspects of X-linked diseases. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 years of FOS. Oxford, UK: Oxford PharmaGenesis, 2006.
  6. Germain DP. Genetics of Fabry disease: diagnostic and therapeutic implications. Presse Med 2007;36 Spec No 1:1S14-19. https://doi.org/10.1016/j.lpm.2006.12.018
  7. Banks DE, Milutinovic J, Desnick RJ, Grabowski GA, Lapp NL, Boehlecke BA. Silicon nephropathy mimicking Fabry's disease. Am J Nephrol 1983;3:279-84. https://doi.org/10.1159/000166730
  8. Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 2005;18:733-38. https://doi.org/10.1038/modpathol.3800344
  9. Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE. Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis 2006;48:844-50. https://doi.org/10.1053/j.ajkd.2006.05.034
  10. Sessa A, Meroni M, Battini G, Maglio A, Brambilla PL, Bertella M, Nebuloni M, Pallotti F, Giordano F, Bertagnolio B, et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001;24 Suppl 2:66-70; discussion 65. https://doi.org/10.1023/A:1012423924648
  11. Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop DF, Schuchman E, Desnick RJ. Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol 1981;103:247-62.
  12. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002;13 Suppl 2:S134-38. https://doi.org/10.1097/01.ASN.0000016684.07368.75
  13. Scheurle C, Dammrich M, Becker JU, Baumgartel MW. Renal phospholipidosis possibly induced by ranolazine. Clin Kidney J 2014;7:62-4. https://doi.org/10.1093/ckj/sft141
  14. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006;5:567-83. https://doi.org/10.1517/14740338.5.4.567
  15. Hruban Z, Slesers A, Hopkins E. Drug-induced and naturally occurring myeloid bodies. Lab Invest 1972;27:62-70.
  16. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Commentary. Lysosomotropic agents. BiochemPharmacol 1974;23:2495-531.
  17. Homewood CA, Warhurst DC, Peters W, Baggaley VC. Lysosomes, pH and the anti-malarial action of chloroquine. Nature 1972;235:50-2. https://doi.org/10.1038/235050a0